Cardio-vascular risk factors, treatment and disease characteristics in the HIV− and HIV+ groups.

1Atrial fibrillation, Myocardial infarction, congestive heart failure, peripheral arteriosclerosis, carotid/coronary arteriosclerosis. 2This information was specifically part of the D.A.D. score and was entered as “yes” vs “no” for Abacavir and as the duration in months for Lopinavir/Ritonavir and Indinavir. Note that there was a strong correlation between the Framingham score and the D.A.D. score in the HIV+ group (r = .67; p<.0001). There was moderate correlations between the Framingham score and the Augmentation Index (r = .31; p<.005) and the D.A.D. score and the Augmentation Index (r = .38; p<.004). Standard assays for Cholesterol, Reference Intervals: 0.0–6.0 mmol/L; Auto Chemistry (8382–9164). Standard assays for HDL Cholesterol, Reference Intervals: >1.0 mmol/L; Auto Chemistry (8382–9164). Standard assays for High-sensitivity C Reactive Protein(hs-CRP), Reference Intervals: <10 mg/L; Auto Immunoassay (8382–9161).